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Abstract: Osteosarcoma is a rare type of cancer that commonly occurs as a primary bone tumour in children and 
adolescents and is associated with a poor clinical outcome. Despite complex treatment protocols, including chemo-
therapy combined with surgical resection, the prognosis for patients with osteosarcoma and metastases remains 
poor and more effective therapies are required. In this study, we evaluated the therapeutic efficacy of sunitinib 
malate, a wide-spectrum tyrosine kinase inhibitor, in a preclinical mouse model of osteosarcoma. Sunitinib signifi-
cantly inhibited proliferation, provoked apoptosis and induced G2/M cell cycle arrest in the human osteosarcoma 
cell lines SaOS-2 and 143B in vitro. Importantly, sunitinib treatment significantly reduced tumour burden, microves-
sel density and suppressed pulmonary metastasis in a 143B cell-derived intratibial osteosarcoma model in SCID 
mice. Sunitinib significantly decreased primary tumor tissue proliferation and reduced tumor vasculature. Our study 
indicates that sunitinib has potential for effective treatment of metastasizing osteosarcoma and provides the frame-
work for future clinical trials with sunitinib alone or in combination with conventional and other novel therapeutics 
aiming at increased treatment efficacy and improved patient outcome. 
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Introduction
Osteosarcoma (OS) is a rare type of cancer 
associated with a variety of genetic abnormali-
ties. It is characterised by local aggressiveness 
and a high metastatic potential, which fre-
quently occurs in the early onset of tumour 
development and results in poor survival of OS 
patients [1]. OS has an incidence of four to five 
cases per million individuals per year and 
occurs mainly in adolescents and young adults, 
with a second peak incidence in patients over 
50 years of age [2]. OS patients diagnosed with 
localised disease and subjected to state-of-
the-art treatment, which includes surgical 
resection of the primary tumour and neo-adju-
vant multidrug combination chemotherapy, 
have a 5-year survival rate of 70% [3]. Patients 
with metastatic disease at diagnosis or with 
recurrent disease, on the other hand, exhibit a 
5-year survival rate of only 20% [4]. The lung is 
the predominant site of OS metastasis and 
lung lesions are the most common cause of 
death in OS patients [5]. Attempts to improve 
therapeutic efficacy by altering chemotherapy 
and radiotherapy combination treatments, and 
also altering dose escalations,has not improved 
OS survival outcomes [6, 7]. Because of the dis-
appointing outcomes of clinical trials involving 
OS, new therapeutics and new approaches to 
treat this disease are urgently needed.
Sunitinib malate (SU-11248) is a small mole-
cule tyrosine kinase inhibitor (TKI) that can pen-
etrate cell membranes. It is metabolized by 
cytochrome P450 3A4 (CYP3A4) to pharmaco-
logically active N-desethyl metabolite SU12662 
[8]. It has been shown to have inhibitory activity 
in a wide spectrum of kinases including plate-
let- derived growth factor receptors (PDGFRα 
and PDGFRβ), vascular endothelial growth fac-
tor receptors (VEGFR1, VEGFR2 and VEGFR3), 
stem cell factor receptor (KIT), Fms-like tyrosine 
kinase-3 (FLT3), colony stimulating factor recep-
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tor type 1 (CSF- b1R) and the glial cell-line 
derived neurotropic factor receptor (RET) [9, 
10]. Sunitinib has been shown to be effective in 
the treatment of many cancers and has recent-
ly been approved for the treatment of patients 
with pancreatic neuroendocrine tumours, renal 
cell carcinoma (RCC) and in advanced solid 
tumours such as gastrointestinal stromal 
tumours (GIST) [11-13]. These findings led us to 
hypothesize that sunitinib may also suppress 
tumour growth and metastasis in OS.
The principal aim of the present study was to 
evaluate in an intratibial osteolytic and sponta-
neously metastasizing OS mouse model the 
suppressive effects of sunitinib malate on pri-
mary tumour growth and lung metastasis. In 
this study, we also determined the in vitro cyto-
toxic effects of sunitinib in the human SaOS-2 
and 143B OS cell lines and used a LacZ and 
m-Cherry expressing 143B cell line derivative 
in the intratibial OS mouse model.
Materials and methods 
Cell culture and reagents
The human OS cell lines SaOS-2 (HTB-85), 
U2OS (HTB-96) and 143B were purchased from 
American Type Culture Collection (Manassas, 
VA, USA). All cell lines were cultured at 37°C 
in a humidified atmosphere of 5% CO2 in 
Dulbecco’s modified Eagle’smedium (DMEM 
containing 4.5 g/l glucose) and Ham F12 
(Invitrogen, Carlsbad, CA, USA) at a 1:1 ratio 
supplemented with 10% fetal calf serum. Cell 
line authentication was performed by multi- 
plex polymerase chain reaction (Microsynth, 
Switzerland) with a PowerPlex®16HS system 
(Promega, USA) and the data verified by com-
parison with those reported in the German 
Collection of Microorganisms and Cell Cultures 
database (DSMZ, Braunschweig, Germany). All 
cells were cultured at 37°C in a humidified 
atmosphere of 5% CO2. Sunitinib was pur-
chased from Bio Vision Inc. (San Francisco, CA, 
USA). For in vitro experiments, stock solutions 
of 100 mM sunitinib in dimethyl sulfoxide were 
diluted in DMEM to the indicated final concen-
trations. For the in vivo studies, sunitinib was 
dissolved in carboxymethylcellulose (CMC) 
solution (CMC 0.5%, NaCl 1.8%, tween 80 0.4% 
and benzyl alcohol 0.9% in distilled water). All 
solvents were purchased from Sigma-Aldrich, 
USA.
Cell proliferation assay
The effects of sunitinib on the growth of OS cell 
lines were assessed with a WST assay as previ-
ously described [14]. The cells were seeded in 
96-well plates at a density of 3 × 103 cells/well 
and allowed to adhere and grow overnight. The 
cells were then treated or untreated with suni-
tinib as indicated in the Figure legends and sub-
sequently incubated for 2-3 h with 10 μl per 
well WST-1 reagent (Roche Diagnostics Corp., 
Indianapolis, IN, USA). Formazan produced 
from WST-1 by mitochondrial dehydrogenase in 
metabolising cells was quantified at 415 nm in 
a scanning multiwell spectrophotometer (Bio-
Rad, Hercules, CA, USA).
Cell cycle analysis
Cell cycle analysis was performed at the Flow 
Cytometry Facility of the Federal Institute of 
Technology (ETH) Zurich. The cells were seeded 
in dishes of 10 cm in diameter at a density of 
1.0 × 106 cells per dish. After initial treatment 
with indicated concentrations of sunitinib for 
24 and 48 h, SaOS-2 and 143B cells were 
treated with trypsin. They were then collected 
by centrifugation and washed with PBS. 
Subsequently, the cells were fixed by incuba-
tion in ice-cold 70% (v/v) ethanol overnight at 
4°C. The cells are then washed with PBS and 
resuspended in 500 μl of ice-cold PI/RNase 
staining buffer (BD Pharmingen AG, Allschwil, 
Switzerland). The resuspended cells were then 
incubated at 37°C for 30 min in the dark. The 
samples were analysed with a fluorescence 
activated cell sorter (FACS; Calibur, BD, USA). 
Only single cells were analysed and the per-
centages of cells in individual phases of the cell 
cycle were calculated using FlowJo software 
(Ashland, MA, USA).
Western blot
After treatment with sunitinib at the indicated 
concentrations, OS cell lines were harvested 
for protein extraction by lysis buffer. The proce-
dures used for western blotting were those 
described previously [15]. Briefly, aliquots of 
protein extracts (30 to 40 μg/lane) were 
separated by SDS-PAGE (BioRad Laboratories, 
Hercules, CA, USA) and wet-transferred to nitro-
cellulose membranes (BioRad Laboratories). 
They were then probed with antibodies to the 
following proteins: endogenous caspase-3 (Cell 
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Signaling, 1:1000); cleaved caspase-3 (Novus 
Biologicals, 1:500); PARP (Cell Signaling, 
1:1000); GAPDH (Santa Cruz, 1:1000) probed 
with secondary isotype specific antibodies 
tagged with horseradish peroxidase (Santa 
Cruz). The bound immuno-complexes were 
detected with Immobilon chemiluminescence 
substrate (Millipore, Billerica, MA, USA) and 
visualized with a VersaDoc system (BioRad 
Laboratories).
cDNA synthesis and expression analysis
Total RNA was isolated from OS cell lines using 
an RNeasy mini kit (Qiagen, Valencia, CA, USA), 
and 1 μg of total RNA was used as atemplate 
for cDNA synthesis with a High-Capacity cDNA 
Reverse transcription kit (Applied Biosystems, 
Foster City, CA, USA). For real time PCR (qRT-
PCR) analysis three independent RNA prepara-
tions from each cell lines were reverse tran-
scribed in a final volume of 10 μl. qRT-PCR was 
performed using the StepOne Plus Real- Time 
PCR system (Applied Biosystems, USA) in 
96-well plates. qRT-PCR was performed using 
following primers CyclinD1 Forward: 5’-TGTTC- 
GTGGCCTCTAAGATGAAG-3’; Reverse: 5’-AGG- 
TTCCACTTGAGCTT-GTTCAC-3’; human cyclinB1 
Forward: 5’-AAGAGCTTTAAACTTTGGTCTGGG-3’, 
Reverse: 5’-CTTTGTAAGTCCTTGATTTA-CCATG- 
3’. The cDNA and appropriate primers were 
added to Power SYBR Green PCR master mix 
(Applied Biosystems, USA) and the samples 
were pre-incubated as follows: 50°C for 2 min 
and at 95°C for 10 min, 40 cycles at 95°C for 
15 s and at 60°C for 1 min. Relative expression 
levels of individual gene transcripts were calcu-
lated by the comparative cycle threshold (ΔΔCT) 
method and normalised to GAPDH transcripts.
Retroviral transduction of LacZ expressing 
143B cells with mCherry fluorescent protein 
(143B/LZ+mC)
A pcDNA3.1 plasmid containing a mCherry 
reporter gene was a generous gift of Professor 
M. Rudin (Institute of Biomedical Engineering, 
University and ETH Zurich). The mCherry gene 
was sub-cloned from this plasmid into a retrovi-
ral pQCXIH vector that contained a hygromycin 
resistance gene. Retroviral particles containing 
pQCXIH-mCherry were produced in HEK 293T 
cells and used for infection, as described previ-
ously [16]. After infection of LacZ-positive 143B 
cells as described previously [17], selection of 
mCherry-positive cells was performed for 1 
week in tissue culture medium containing 
400 μg/ml of hygromycin (Merck, Darmstadt, 
Germany). The infection efficacy and the pres-
ence of mCherry-positive 143B cells were 
assessed by fluorescence microscopy (Zeiss 
Observer Z1, Zeiss Microscopy, Jena, Germany).
Animals
Female 6-7 week old immunosuppressed SCID 
mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany) and main-
tained in individually ventilated cages. Housing 
and experimental protocols were in accordance 
with the Swiss Animal Protection Law and in 
compliance with the regulations of the 
Veterinärmt, Kanton Zurich. All manipulations 
were carried out under sterile conditions in a 
laminar flow hood.
Intratibial injection of 143B/LZ+mC OS cells
Exponentially growing 143-B/LZ+mC cells were 
harvested by trypsinisation and washed thor-
oughly with PBS. 5 × 105 cells in 10 µl of PBS 
were orthotopically injected with a Hamilton 
syringe into the medullar cavity of the left proxi-
mal tibia of the mice. Prior to injection, the 
tibia plateau was opened by punching with a 
26-gauge needle.  Tumour growth and osteoly-
sis were monitored by means of X-ray analysis 
once a week with the Faxitron® MX-20 
Specimen Radiography System (Faxitron X-Ray 
LLC, Lincolnshire, IL, USA). The tumour volume 
(V) in individual mice was calculated from mea-
surements with a caliper rule of the largest (L) 
and the smallest (S) perpendicular diameters of 
the tumour cell-injected and the healthy control 
leg. V was calculated as the difference between 
the volume (=0.5 × L × (S) 2) of the tumour leg 
and the volume of the control leg. The organs 
and legs of the mice were prepared at sacrifice 
and primary tumors and metastases were 
stained with 5-bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal). For the quantification of 
macro and micrometastases in the lung of indi-
vidual mice, images of the surface of one lung 
lobe were taken under a Nikon Eclipse E600 
microscope with a Kappa PS 20 C digital 
camera (Kappa Optronics GmbH, Gleichen, 
Germany). Indigo-blue stained foci on lung sur-
faces with a diameter >0.1 mm were defined as 
macrometastases, and foci with a diameter 
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<0.1 mm were defined as micrometastases. 
The results are presented as the means ± SEM 
of the number of respective lung metastases 
counted in atleast ten tumour bearing mice. 
Treatment of mice with sunitinib
Sunitinib at dosesof 40 and 80 mg/kg was 
administered in CMC solution daily with an oral 
gavage while mice in the control group were 
treated with CMC solution alone. The treatment 
of 143B/LZ+mC tumour bearing mice with suni-
tinib was started when mCherry fluorescent 
intratibial lesions became detectable by IVIS. 
The mice (n=30) were then randomly distribut-
ed into three groups (control, 40 mg/kg, 80 
mg/kg) with 10 mice per group. After treatment 
for 12 days, all mice were euthanized and their 
tumours and organs were excised and stored in 
4% paraformaldehyde until they were used for 
immunohistochemical analysis.
In vivo bioluminescent imaging (IVIS) of 
mCherry fluorescence
Whole body imaging of mCherry fluorescence in 
mice with 143B/LZ+mC cell-derived intratibial 
primary tumours was performed weekly with an 
IVIS imaging system (Caliper Life Sciences, Inc. 
Hopkinton, MA, USA). Prior to in-vivo imaging, 
the mice were anesthetised with isoflurane. 
Photon emission was quantified in photons/
sec/cm2 with Living Image 3.1 software 
(Xenogen Corporation, MA, USA). 
Immunohistochemistry (IHC)
Angiogenesis was examined by immunohisto-
chemistry with rabbit polyclonal CD31 antibod-
ies that immunostained vascular endothelial 
cells (Abcam, UK (dilution 1:250). Briefly, tu- 
mour sections were fixed in 4% paraformalde-
hyde and dehydrated by serial incubation in 
70%, 96% and 100% ethanol and xylene and 
then embedded in paraffin. Tissue sections of 
6 µm were mounted onto slides, deparaffinised 
and rehydrated and then heated in 0.1 M citrate 
buffer (pH 5.8) for antigen retrieval. Endogenous 
peroxidase activity was inactivated by incuba-
tion of the tissue sections in 3% H2O2 for 10 
min at RT. The sections were washed with PBS 
(pH 7) twice, incubated in blocking buffer (10% 
goat serum and 0.1% Tween in PBS) for 1 h 
at room temperature and then incubated with 
CD31 primary antibody (1:150 final dilution) 
overnight at 4°C. After extensive washing with 
blocking medium, secondary Alexa Fluor 
546-labeled antibodies to rabbit IgG (Life 
Technologies) at a final dilution of 1:200 were 
added to the cells and they were incubated for 
30 min in the dark. Nuclear DNA was stained 
with 0.2 μg/ml DAPI (4’, 6’-diaminidino-2-phe-
nylindole) (Molecular Probes Inc., Eugene, USA). 
The coverslips were then washed with PBS and 
dipped in H2O and then mounted in Immomount 
(ThermoScientific; Waltham, MA). Fluorescence 
was detected with a Nikon Eclipse E600 micro-
scope equipped with appropriate filter blocks 
(Nikon Corporation, Tokyo, Japan). Ki67 indicat-
ing tissue proliferation was immunostained 
with a rabbit antibody (Abcam, UK) at 1:200 
final dilution and secondary anti-rabbit antibod-
ies (1:2000 final dilution) from Santa Cruz. 
Ki67 immunostained cells were quantified with 
Image J software.
Microvessel density (MVD) analysis
Rabbit polyclonal CD31 antibody was used as a 
blood vessel endothelial marker. Vessel density 
was determined by counting the number of 
CD31-positive vessels per viable tumour area. 
Five areas with the highest density of microves-
sels were viewed at a higher magnification (200 
×) to determine the mean ± SEM of MVD.
Statistical analysis
Data were plotted and analysed using Student’s 
t test. The Prism 4 program (GraphPad soft-
Figure 1. Sunitinib malate inhibits growth and induces apoptosis in OS cells in vitro. A. SaOS-2 and 143B cells 
were incubated for 24 h with indicated concentrations of sunitinib or DMSO as a control and proliferation was then 
assessed by WST-1 assay. Data are the mean ± SEM of three independent experiments normalized to respective 
DMSO controls (*P<0.05 compared to control). B. Cell cycle analysis of SaOS-2 and 143B cells treated for 24 h 
and 48 h with indicated concentrations of sunitinib or DMSO as a control. The numbers of cells in indicated growth 
phases are illustrated in percentage of the total number of cells analysed. C. Analysis of expression of mRNA encod-
ing indicated cell-cycle regulating genes by real time PCR in SaOS-2 and 143B cells treated for 24 h with 5 μM suni-
tinib or DMSO as a control. The mRNA levels were normalised to those of GAPDH and to controls (n=3) (*P<0.01). D. 
Western blot analysis of caspase 3 and PARP cleavage in SaOS-2 and 143B cells treated for indicated time periods 
with sunitinib or DMSO as a control. GAPDH was used as a protein loading control. Representative experiment was 
carried out three times.
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Figure 2. Sunitinib inhibits osteolytic tumor development in a metastasizing intratibial human xenograft OS model 
in SCID mice. A. Representative images of mCherry fluorescent tumours developing in hind limbs of mice intratibi-
ally injected with 143B/LZ+mC cells and treated daily for indicated time periods with CMC solution (control, upper 
panel), or with 40 mg/kg (middle panel) or 80 mg/kg (lower panel) sunitinib. Colour scale is shown, representing 
photons/sec. B. Quantitative analysis of mCherry fluorescence of 143B/LZ+mC cell-derived intratibial tumours in 
mice after 12 days of treatment as indicated. Data are the mean ± SEM of 10 mice analysed per group; *P<0.05. 
C. Representative X-ray images of hind limbs of mice with 143B/LZ+mC cell-derived osteolytic intratibial tumors 
(arrows) treated for time periods with CMC solution or sunitinib as indicated. D. Effect of sunitinib treatment in 
primary tumour growth over time in mice intratibially injected with 143B/LZ+mC cells in each of the three group 
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ware, Inc., San Diego, CA, USA) was used for the 
statistical analysis. P<0.05 was considered 
statistically significant. The data are presented 
as means ± SEM of the indicated number of 
independent experiments.
Results
Sunitinib malate inhibits proliferation and pro-
vokes apoptosis in OS cell lines in vitro
Effects of the tumour suppressive tyrosine 
kinase inhibitor sunitinib on proliferation, cell 
cycle control and apoptosis were studied in 
osteoblastic SaOS-2 and osteoclastic 143B 
cells. Treatment of OS cell lines for 24 h with 2 
μM and 5 μM sunitinib inhibited proliferation in 
a dose-dependent manner as assessed by 
WST-assay (Figure 1A) and these results are 
similar to those observed in in vitro studies of 
other sunitinib-treated tumour cell lines [18]. A 
flow cytometric cell cycle analysis of SaOS-2 
and 143B OS cells treated for 24 h and 48 h 
with 5 μM revealed a time dependent decrease 
of percentage of cells in the G1 phase and a 
concomitant accumulation of cells in the G2 
phase (Figure 1B). Treatment of SaOS-2 cells 
with sunitinib increased the percentage of cells 
in the G2 phase from 16.4% to 30.2% after 
24 h and to 56.4% after 48 h of treatment. 
Similarly, exposure to sunitinib increased the 
percentage of 143B cells in the G2 phase from 
17.3% at 0 h to 21.3% at 24 h and 35.3% after 
48 h (Figure S1). To determine whether suni-
tinib affected the expression levels of the cell 
cycle proteinscyclin D1 (a protein required for 
the G1/S transition) and cyclinB1 (a key regula-
tor of the cell transition from G2 to the M ph- 
ase) qRT-PCR was performed to measure their 
expression levels in SaOS-2 and 143B cells. In 
SaOS-2 and 143B cells treated with 5 μM 
sunitinib there were no significant changes in 
cyclinD1 expression levels at 48 h as com- 
pared to the control, however cyclinB1 levels 
decreased to 1.5-fold in SaOS-2 cells and 1.2-
fold in 143B cells (Figure 1C). These results 
suggested that downregulation of the G2 
phase-regulating protein cyclinB1 contributed 
to sunitinib mediated cell cycle arrest in OS 
cells leading to apoptosis.
Time dependent enhancement of cell apopto-
sis by sunitinib was observed in SaOS-2 and 
143B cells as indicated by changes in the cell 
morphology and the cells became round and 
detached at 72 h (Figure S2). To further confirm 
that the observed apoptosis was induced by 
sunitinib, immunoblotting was performed on 
total cell lysates after sunitinib treatment at 5 
μM for 24, 48 and 72 h to detect the activation 
of caspase-3 and the cleavage of poly (ADP-
ribose) polymerase (PARP), which are markers 
of cells undergoing apoptosis. Sunitinib mark-
edly induced apoptosis in 143B and SaOS-2 
cells by increasing the levels of cleaved cas-
pase-3 and cleaved PARP in a time-dependent 
manner (Figure 1D).
Sunitinib malate inhibits the growth of intrati-
bial OS xenografts in mice
The in vitro experiments showed that the treat-
ment of OS cell lines with sunitinib inhibited cell 
growth and provoked apoptosis. Consequently, 
tumour suppressive effects of sunitinib were 
studied in SCID mice intratibially injected with 
143-B/LZ+mC cells (Figure 2). Daily treatment 
with CMC solution (vehicle control) or with suni-
tinib was started on day 10 after tumour cell 
injection when mCherry fluorescence of the 
intratibial primary tumours became detectable 
by the IVIS in mice (Figure 2A). Sunitinib treat-
ment for 12 days resulted in a significant and 
dose-dependent reduction of tumour fluores-
cence in treated compared to control animals 
(Figure 2A and 2B) consistent with a sunitinib 
dose-dependent inhibition of intratibial tumor 
growth over time visualised by x-ray imaging 
(Figure 2C) and assessed by caliper ruler mea-
surements (Figure 2D). The mean tumour vol-
ume at sacrifice on day 22 assessed by caliper 
measurements was 126.9±73.1 mm3 in control 
animals, and 50.30±36.6 mm3 or 39.4±20.2 
mm3 in mice treated daily with 40 or 80 mg/kg 
sunitinib, respectively.
Importantly, the x-ray analysis also showed a 
notable sunitinib dose-dependent attenuation 
of osteolysis caused by the developing tumors 
(Figure 2C). Interestingly and presumably as a 
side effect of the treatment with sunitinib the 
mice that received 80 mg/kg of the drug per 
day for 12 days displayed a significant loss of 
body weight. The loss of body weight was less 
pronounced and not significant in animals that 
(n=10) (*P<0.01). E. Body weight of mice treated for indicated time periods with CMC solution or with 40 or 80 mg/
kg sunitinib (n=10) (**P<0.001).
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Figure 3. Sunitinib suppresses spontaneous lung metastasis in mice bearing intratibial 143B/LZ+mC cell derived 
tumours. (A) Representative images of whole mounts of X-gal–stained lungs of mice treated with vehicle (control) or 
with sunitinib as indicated. The lungs were collected at sacrifice of the mice on day 22 after intratibial inoculation 
of 143B/LZ+mC cells. The arrowheads point to blue macrometastases (>0.1 mm in largest dimension). Size bar=2 
mm. (B) Representative microscopic images of lung micrometastases (<0.1 mm in largest dimension) observed on 
the whole lung mounts. Arrows point to X-gal–stained lesions. Bars=250 μm. (C) Quantification of macrometastases 
on the whole mounts of lungs collected from the mice described in (A). (D) Quantification of pulmonary micrometas-
tases. Data in (C and D) are the mean ± SEM numbers of lung macro- and micrometastases per mouse in indicated 
treatment groups of 10 animals; *P<0.05, **P<0.01.
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Figure 4. Sunitinib reduces microvessel density and proliferation in intratibial 143B/LZ+mC cell-derived OS xeno-
grafts. A. Representative microscopic images (20×) of nuclear DAPI staining (left panels) and of CD31 immuno-
flourescent staining (right panels) of paraffin sections of primary tumour tissue collected from mice treated with 
CMC solution alone (control) or with 40 or 80 mg/kg sunitinib. The top right panel shows control immunoflourescent 
staining with secondary Alexa Fluor 546-labeled antibodies to rabbit IgG (anti-rabbit) alone. B. Representative mi-
croscopic images of IHC staining of Ki67 in tumours in paraffin sections of primary tumor tissue of 143B/LZ+mC 
xenografts treated with control or 40 and 80 mg/kg sunitinib. Scale bars=100 μm. C. Quantitative analysis of mi-
crovessel density assessed by CD31 immunoflourescent staining (n=5) *P<0.005. D. Quantification of tumour cell 
proliferation using Ki-67 staining. Data are expressed as Ki-67 positive tumour cells as percentage of total tumour 
cells. (n=5) **P<0.002.
Sunitinib therapy in experimental osteosarcoma
2165 Am J Cancer Res 2015;5(7):2156-2168
were treated with 40 mg/kg sunitinib per day 
(Figure 2E).
Sunitinib malate suppresses spontaneous pul-
monary metastasis of intratibial OS xenografts
To determine whether treatment with sunitinib 
also influences spontaneous lung metastases 
formation, metastatic lesions on the lung sur-
face were analysed by X-gal staining after sacri-
fice of the mice on day 22. Comparison of whole 
mounts of lungs after x-gal staining revealed an 
obvious inhibition of macrometastasis in the 
sunitinib treated groups with respect to the 
control mice (Figure 3A). The mean numbers of 
macrometastases in the control mice was 
40±4.5 per lung while in 40 mg/kg and 80 mg/
kg sunitinib-treated mice the mean numbers 
was 10±4.5 and 3±6.7, respectively (Figure 
3C). Evaluation of the mean number of X-gal-
stained macrometastases on the lung surface 
revealed a significant decrease by 64% in the 
40 mg/kg and 72% in the 80 mg/kg sunitinib 
treatment groups. Examination at the micro-
scopic level showed that the formation of micro-
metastases was clearly suppressed in the suni-
tinib treated groups (Figure 3B). The mean 
number of micrometastases in the control mice 
was 374±63.8 while in 40 and 80 mg/kg suni-
tinib the mean numbers was 118.1±35.83 and 
35±11.7 per lung, respectively (Figure 3D). The 
micrometastatic lesion was eventually reduced 
to 66% and 75% in the 40 mg/kg and 80 mg/
kg sunitinib treatment group, respectively when 
compared to the control group.
Sunitinib malate reduces microvessel density 
and tumour cell proliferation in intratibial OS 
xenografts
Angiogenesis in intratibial 143-B/LZ+mC cell-
derived tumours in vehicle (control) and suni-
tinib treated mice was examined by CD31 
immunoflourescent staining of vascular endo-
thelial cells in paraffin sections of tumour tis-
sue collected at sacrifice. Control tumours were 
characterised by CD31 positive microvascular 
endothelium that displayed linked segments of 
irregular microvessels while the tumours treat-
ed with 40 and 80 mg/kg sunitinib a fewer and 
more isolated CD31 positive microvessels were 
identified (Figure 4A). The mean number of 
CD31 positive cells in the control mice was 
38±7.5 while in 40 mg/kg and 80 mg/kg suni-
tinib-treated mice the mean numbers were 
24±6.5 and 15±4.7, respectively (Figure 4C). 
Quantitative analysis of the density of these 
microvessel-like structures in dissected 
tumours revealed a significant decrease of 
45% and 54% in mice treated with 40 mg/kg 
and 80 mg/kg sunitinib, respectively, com-
pared to the control group. In addition, tumour 
proliferation as determined by Ki67 nuclear 
antigen staining was analysed in 143-B/LZ+mC 
cell xenografts from the three groups (Figure 
4B). The mean number of Ki67 positive cells in 
the control mice was 63±6.5 while in 40 mg/kg 
and 80 mg/kg sunitinib-treated mice the mean 
numbers was 52±7.6 and 38±6.7, respectively 
(Figure 4D). A quantitative analysis of the num-
ber of proliferating cells in the tumours collect-
ed from mice of the different treatment groups 
revealed a significant and dose-dependent 
decrease of Ki67 expressing cells by 52% and 
68% in tumours of mice treated with 40 mg/ 
kg and 80 mg/kg sunitinib, respectively, com-
pared to the number of proliferating cells 
observed in control animals.  
Discussion
OS is a rare but devastating disease and metas-
tasizing OS in particular remains largely treat-
ment resistant, reflected by a long-term surviv-
al rate of only 20 to 30%. Consequently, novel 
therapeutics are urgently needed. Previous 
preclinical studies, which demonstrated that 
the wide-spectrum kinase inhibitor sunitinib 
with tumor suppressive activity prevented bone 
metastasis in renal cell cancer (RCC) and 
breast cancer mouse models [19, 20], and a 
recent report on an ongoing clinical trial with 
sunitinib in a phase II setting (NCT01391962; 
https://clinicaltrials.gov) in patients suffering 
from alveolar soft part sarcoma prompted us to 
investigate in the present study primary tumor 
and metastasis suppressive effects of sunitinib 
in a spontaneously metastasizing intratibial 
human xenograft OS mouse model largely 
reproducing the human disease.
Initial experiments in vitro with the human 
osteoblastic SaOS-2 and the osteoclastic 143B 
OS cell lines revealed results similar to those 
reported from studies with other tumour cell 
lines treated with sunitinib [18]. Sunitinib sig-
nificantly and dose-dependently inhibited pro-
liferation and promoted apoptosis. A cell cycle 
analysis of sunitinib treated cells demonstrated 
a remarkable increase of a sub-population of 
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cells in the G2 phase of the cell cycle, suggest-
ing that sunitinib caused a G2/M-arrest, which 
is in accordance with the findings of other stud-
ies investigating sunitinib treated cells [21-23]. 
The G2/M arrest, which is also consistent with 
the observed downregulation of cyclinB1 by 
sunitinib, appears to allow OS cells to enter 
mitosis andforce them to undergo apoptosis.
The in vivo studies in SCID mice were carried 
out with the osteolytic 143-B/LZ+mC OS cells, 
which allowed us to access primary tumour 
growth in vivo by monitoring mCherry fluores-
cence and the detection at the single-cell level 
of 143-B/LZ+mC cells metastasizing to the 
lung. Tumour growth over time and osteolysis 
were comparable to that previously described 
for 143-B/LZ cells in the intratibial mouse 
model [24]. Although we were unable to obtain 
bone density scan data, X-ray imaging showed 
the expected inhibition of osteolysis in mice 
with sunitinib.Interestingly, the inhibition of 
tumour growth in sunitinib treated mice over 
time observed in the present study was similar 
to that reported for sunitinib used at compara-
ble doses in xenograft models of triple negative 
breast cancer and prostate cancer [25-27]. The 
doses of sunitinib used in this study (40 and 80 
mg/kg) were intended to yield serum levels of 
the drug similar to those reached in a clinical 
setting in cancer patients [28, 29]. Oral doses 
of sunitinib at 50-150 mg/kg were also shown 
to evoke a good tumour response and a man-
ageable toxicity profile in adult patients [28]. 
Recent studies in patients with metastatic RCC 
showed that increased doses of sunitinib were 
well tolerated and further improved the clinical 
outcome by inhibiting primary tumour growth 
as well as metastasis [30]. In the present study, 
mice orally treated with sunitinib showed a sig-
nificant decrease in the number of primary 
tumour cells that disseminated to the lung. 
Since lung metastasis is the main cause of 
death in OS patients [5], metastasis suppres-
sive efficacy is a major requirement for a novel 
drug considered to improve the clinical out-
come of OS patients. The effect of sunitinib in 
supressing metastasis has been studied in 
breast [31, 32] and RCC [22] mouse models. 
An important pathophysiological feature of OS 
is hypervascularisation [33] and VEGF, a key 
regulator of angiogenesis, is considered as a 
prognostic marker for poor outcome in OS [34]. 
This suggests that anti-angiogenic drugs could 
be beneficial for OS treatment as they may 
inhibit OS tumour vascularisation. Since anti-
angiogenic properties of sunitinib have been 
reported [11-13] we also looked for effects of 
sunitinib on blood vessel formation in the pri-
mary tumours of our OS mouse model. The 
observed decrease in MVD in sunitinib treated 
compared to non-treated control mice suggest-
ed that sunitinib targeted regulatory molecules 
such as VEGFR and inhibited blood vessel 
formation in this experimental OS model. 
Importantly and in good agreement with the 
results of our in vitro studies and with the 
results of studies in xenograft models of colon 
and prostate cancers [35, 26], sunitinib also 
reduced significantly the proliferative activity of 
the intratibial OS primary tumour tissue, which 
is in line with the observed slower growth of 
the tumours assessed by mCherry bio-fluores-
cence imaging and caliper ruler measure- 
ments. 
A considerable limitation of the relevance of 
the current study is the fact that the progress of 
the disease could not be monitored over a lon-
ger period of time. Due to the weight loss of 
mice in response to daily oral sunitinib adminis-
tration, the animals had to already be sacrificed 
after 12 days of treatment. Weight loss of mice 
during administration of sunitinib has been 
reported in other experimental models [36, 
37]. The mechanisms of weight loss due to 
sunitinib treatment are poorly understood. 
However, sunitinib has been reported to target 
fat cells, thereby causing loss of appetite [38]. 
Thus, the weight loss of sunitinib treated ani-
mals observed in the present study might be 
avoidable in future studies if the animals are 
put on a high fat diet during sunitinib 
treatment.
In conclusion, the data of the present study in a 
spontaneously metastasizing intratibial human 
xenograft OS mouse model clearly indicate that 
daily oral administration of sunitinib slowed 
down tumour growth, reduced primary tumour 
vascularisation and inhibited the lung metasta-
sis. While the efficacy of sunitinib alone and in 
combination with other drugs has already been 
reported in various pre- and clinical studies in 
other cancer types, our results indicate that 
sunitinib could also be effective in the treat-
ment for OS.
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Figure S1. Cell cycle analysis of SaOS-2 and 143B cells treated with sunitinib. Cell cycle analysis of SaOS-2 and 143B cells treated with sunitinib. Effects of the 
treatment of SaOS-2 and 143B cells for 24 h with 5 µM sunitinib on the cell cycle were evaluated by propidium iodide (PI) staining of the cells and subsequent FACS 
analysis.
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Figure S2. Phase contrast microscopic images of SaOS-2 and 143B cells treated with sunitinib for indicated time 
periods.
